Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Visma eyeing up London for stock market debut - report

(Sharecast News) - Norway's Visma is planning a City debut, it was reported on Thursday, in a rare win for the under-pressure London Stock Exchange. Visma, which supplies accounting and payroll software to small and medium-sized companies, has been majority owned by British private equity firm Hg since 2006.

It has grown significantly since then, however, and is now thought to be valued at around €19bn.

Hg therefore wants to float the business, and has opted for London over Amsterdam, the Financial Times reported.

The newspaper said London had been selected because of its deep capital markets and range of investors, citing unnamed people familiar with the deliberations.

However, it also noted that the listing - which is potentially slated for early next year - was dependent on promised government reforms, which sources said where essential to outweigh complications caused by Brexit.

The London stock market is enduring a difficult period, as companies either favour other exchanges or going private. Last year, a total of 88 firms delisted or transferred their primary listing. Only 18 companies joined the market.

Visma, which lends its name to the leading Dutch cycling team Visma-Lease a Bike, has around 1.4m customers across the Nordics, Benelux, central and eastern Europe and Latin America.

It posted pre-tax profits of €185m on revenues of €2.8bn in 2024.

Hg, which currently owns around 70% of the business, is expected to retain a stake post IPO, the FT noted.

Both Hg and Visma have yet to comment on the report.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.